Stock listing

ASX:IVX Invion Ltd. Share Price

Home listing (ASX) of Invion Ltd.

Follow Invion Ltd. into a list and get an email when it puts out news.

Share price · ASX:IVX

$0.034 AUD 0.000 (0.0%)

Close on Nov 19, 2026

Past year -58.0% · daily closes, Nov 20, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.034 – $0.034 AUDNov 19, 2026
Volume
36 sharesNov 19, 2026
Market cap
$3.76M AUDAt the close on Nov 19, 2026 · price × 110.6M shares outstanding
52-week range
$0.032 – $0.110 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$3,462 AUDMedian day 28,893 shares · last 3 months, Aug 19, 2026 – Nov 19, 2026
Invion Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:IVX · Home$0.034 AUD0.000 (0.0%)36$0.034$0.034$0.034$0.034Close on Nov 19, 2026
Frankfurt:7C8€0.021 EUR0.000 (0.0%)—€0.021€0.021€0.021€0.021Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:IVX · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0340.0000.0%$0.034$0.034$0.03436
$0.0340.0000.0%$0.033$0.034$0.03326,383
$0.034-0.003-8.1%$0.034$0.034$0.0345,000
$0.037+0.004+12.1%$0.037$0.037$0.03715,005
$0.033-0.004-10.8%$0.034$0.034$0.033183,503
$0.037+0.003+8.8%$0.037$0.037$0.03792
$0.034-0.003-8.1%$0.037$0.037$0.03417,165
$0.037+0.003+8.8%$0.037$0.037$0.03710,094
$0.034-0.003-8.1%$0.034$0.035$0.0344,775
$0.0370.0000.0%$0.036$0.037$0.03613,000
$0.0370.0000.0%$0.037$0.037$0.037718
$0.037+0.004+12.1%$0.036$0.037$0.036149,330
$0.033+0.001+3.1%$0.033$0.033$0.033157,500
$0.032-0.004-11.1%$0.037$0.040$0.032387,993
$0.036-0.002-5.3%$0.038$0.038$0.036305,623
$0.038+0.004+11.8%$0.035$0.038$0.035161,342
$0.034-0.001-2.9%$0.035$0.035$0.03427,010
$0.0350.0000.0%$0.034$0.035$0.0342,690
$0.035-0.002-5.4%$0.037$0.037$0.03528,423
$0.037+0.003+8.8%$0.037$0.039$0.035202,556
$0.034-0.004-10.5%$0.037$0.037$0.034204,823
$0.038-0.002-5.0%$0.042$0.042$0.0382,877
$0.040-0.002-4.8%$0.040$0.040$0.04017,500
$0.042+0.004+10.5%$0.038$0.042$0.038176,435
$0.0380.0000.0%$0.038$0.038$0.03871
$0.038+0.001+2.7%$0.038$0.038$0.03871
$0.037-0.001-2.6%$0.038$0.038$0.037519,900
$0.0380.0000.0%$0.039$0.039$0.03850,000
$0.0380.0000.0%$0.038$0.038$0.03829,362
$0.038-0.001-2.6%$0.040$0.040$0.038123,956
$0.039-0.006-13.3%$0.044$0.044$0.03934,351
$0.0450.0000.0%$0.045$0.045$0.0452,371
$0.0450.0000.0%$0.045$0.045$0.0454
$0.045+0.002+4.7%$0.044$0.045$0.04488,117
$0.043+0.005+13.2%$0.040$0.043$0.040125,000
$0.038-0.002-5.0%$0.038$0.038$0.0384,929
$0.0400.0000.0%$0.040$0.040$0.03852,829
$0.040+0.004+11.1%$0.039$0.040$0.039178,929
$0.0360.0000.0%$0.036$0.038$0.036160,400
$0.036-0.001-2.7%$0.039$0.039$0.03639,612
$0.0370.0000.0%$0.037$0.037$0.03711,000
$0.037+0.001+2.8%$0.037$0.037$0.0375,000
$0.036-0.002-5.3%$0.036$0.036$0.0361,059
$0.038-0.001-2.6%$0.037$0.039$0.036320,735
$0.039+0.002+5.4%$0.037$0.039$0.036167,604
$0.037-0.001-2.6%$0.039$0.039$0.03733,160
$0.038+0.001+2.7%$0.038$0.038$0.03810,000
$0.0370.0000.0%$0.041$0.041$0.037447,485

Splits

3 splits since 2011 · ASX:IVX · every price before a split is adjusted for it

DayRatioWhat
1-for-100Consolidation
1.2663-for-1Split
1.028-for-1Split
Ticker
ASX:IVX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Invion Ltd. news

Invion Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 133 in all · newest Nov 18, 2026 · oldest 2016
Decks
45 decks · latest Apr 22, 2026

Where Invion Ltd. is listed

ListingExchangeCountryCurrency
ASX:IVX · Home listing · This pageASXAustraliaAUD
Frankfurt:7C8FrankfurtGermanyEUR
OTC:IVIXFOTCUnited StatesUSD

Valuation

EV/sales 12.2× against a median of 28.0×: 2nd lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 19, 2026

Enterprise value
$4.71M AUD
P/E
Loss
EV/sales
12.2×
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
100.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
Bioxytran, Inc. · OTC:BIXTUS$2.66MUS$2.59Mn/an/an/an/an/an/a-1.20
BioAtla, Inc. · NASDAQ:BCABUS$2.58MUS$2.01Mn/an/an/an/an/an/a-0.34
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Median of the othersUS$2.41MUS$2.10M0.7×28.0×0.3×−63.4%0.0×1.10

Team and board

Officers

OfficerRole
Thian ChewExecutive Chair and CEO
Melanie LeydinNon-Executive Director, Company Secretary & CFO
Louise WhiteExecutive Manager

Board

DirectorRole
Robert RamsayChair of the Board
Thian ChewExecutive Chair and CEO
Alan YamashitaNon-Executive Director
Melanie LeydinNon-Executive Director, Company Secretary & CFO
Paul FieldNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 29, 2025+3.9%
Q2 2025Feb 28, 2025−3.6%
Q2 2023Feb 23, 2023 · After close−6.7%
Q4 2022Aug 17, 2022 · After close0.0%
Q2 2022Feb 22, 20220.0%
Q4 2021Aug 4, 20210.0%
Q2 2021Feb 25, 20210.0%

Open Events

Decks

DeckKindSlidesDate
BIONNOVA 2026Conference17 slidesApr 22, 2026
EMERGENCE 2026 Investment ConferenceConference15 slidesFeb 19, 2026
Shareholder Meeting (November 2025)Shareholder meeting15 slidesNov 26, 2025
Investor Presentation (June 2025)Investor deck29 slidesJun 4, 2025
Shareholder Meeting (November 2024)Shareholder meeting20 slidesNov 14, 2024
Investor Presentation (September 2024)Investor deck25 slidesSep 19, 2024
BioCentury-BayHelix East-West Summit 2024Conference29 slidesMar 5, 2024
Shareholder Meeting (November 2023)Shareholder meeting19 slidesNov 29, 2023
Investor Presentation (October 2023)Investor deck18 slidesOct 24, 2023
Shareholder Meeting (April 2023)Shareholder meeting12 slidesApr 6, 2023
All 45 decks
DeckKindSlidesDate
Shareholder Meeting (November 2022)Shareholder meeting18 slidesNov 17, 2022
AusBioInvest 2022Conference23 slidesOct 27, 2022
11th Annual Australian Microcap Investment Conference (October 2022)Conference21 slidesOct 18, 2022
Investor Presentation (June 2022)Investor deck20 slidesJun 27, 2022
Investor Presentation (February 2022)Investor deck13 slidesFeb 3, 2022
Shareholder Meeting (November 2021)Shareholder meeting8 slidesNov 9, 2021
Shareholder Meeting (October 2020)Shareholder meeting13 slidesOct 21, 2020
Shareholder Meeting (November 2019)Shareholder meeting32 slidesNov 4, 2019
Corporate Update (February 2019)Corporate update35 slidesFeb 28, 2019
Shareholder Meeting (November 2018)Shareholder meeting15 slidesNov 13, 2018
Investor Presentation (February 2018)Investor deck37 slidesFeb 12, 2018
Investor Presentation (December 2017)Investor deck37 slidesDecember 2017
Shareholder Meeting (November 2017)Shareholder meeting24 slidesNov 30, 2017
Shareholder Meeting (November 2017)Shareholder meeting25 slidesNov 30, 2017
Shareholder Meeting (November 2016)Shareholder meeting13 slidesNov 14, 2016
Shareholder Meeting (November 2015)Shareholder meeting33 slidesNov 18, 2015
Investor Presentation (November 2015)Investor deck31 slidesNov 10, 2015
Investor Presentation (September 2015)Investor deck35 slidesSep 7, 2015
Investor Presentation (August 2015)Investor deck36 slidesAug 6, 2015
Investor Presentation (July 2015)Investor deck10 slidesJul 27, 2015
Investor Presentation (July 2015)Investor deck35 slidesJuly 2015
Corporate Update (June 2015)Corporate update11 slidesJun 16, 2015
Investor Presentation (March 2015)Investor deck32 slidesMar 20, 2015
Shareholder Meeting (November 2014)Shareholder meeting24 slidesNov 21, 2014
Investor Presentation (June 2014)Investor deck33 slidesJun 6, 2014
Investor Presentation (April 2014)Investor deck30 slidesApr 9, 2014
Investor Presentation (February 2014)Investor deck27 slidesFeb 26, 2014
Shareholder Meeting (November 2013)Shareholder meeting32 slidesNov 22, 2013
Investor Presentation (October 2013)Investor deck38 slidesOct 28, 2013
Investor Presentation (September 2013)Investor deck25 slidesSeptember 2013
AsiaBiotech Invest 2013Conference32 slidesJun 3, 2013
Investor Presentation (June 2013)Investor deck31 slidesJune 2013
Investor Presentation (April 2013)Investor deck18 slidesApr 2, 2013
Investor Presentation (February 2013)Investor deck19 slidesFeb 25, 2013
Investor Presentation (September 2012)Investor deck27 slidesSep 11, 2012

Open Decks

Financings

RaiseDateIn US dollars
Securities
Announced: raise
Sep 29, 2026
Convertible director loans
Announced: A$400,000 · A$0.05 a share
Buyers: Prof Thian Chew (Up to $200,000 loan); Alan Yamashita (Up to $200,000 loan)
Insiders: Loans provided by Executive Chair & CEO Prof Thian Chew and Non-Executive Director Alan Yamashita, up to $200,000 each
Use of proceeds: Working capital requirements
Sep 29, 2026US$279,335

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue385.3K03.69M4.10M3.29M2.33M3.48M3.88M737.7K0
Cost of revenue1.29M2.69M2.90M2.32M1.52M1.56M2.26M370.9K1.24M
Gross profit385.3K-1.29M1.00M1.21M969.1K810.5K1.92M1.63M366.8K-1.24M
Research and development1.48M1.29M2.69M2.90M2.32M1.52M1.55M2.23M363.7K30.9K
Selling, general and administrative2.12M2.02M1.33M1.05M1.12M844.7K759.6K1.41M769.3K318.7K
Operating income-3.94M-5.29M-5.68M-1.65M-2.32M-1.57M-1.03M-2.52M-960.5K-2.09M
Depreciation and amortization1.72M4.81M816.0K683.1K422.4K277.9K277.9K309.6K1.33M1.24M
EBITDA-2.22M-471.8K-4.86M-965.4K-1.90M-1.29M-748.6K-2.21M364.7K-840.4K
Interest expense346.8K694.8K240.0K53000117.9K144.4K
Income before tax-5.63M-8.81M-5.63M-1.61M-2.24M-1.48M-953.9K-2.55M-926.5K-6.46M
Income tax-33193.9K33137.7K-163.3K-4.26M
Net income-5.63M-8.81M-5.63M-1.61M-2.24M-1.48M-953.9K-2.55M-926.5K-2.20M
Earnings per share, basic-0.06-0.12-0.09-0.03-0.04-0.00-0.00-0.00-0.02-0.14

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents592.3K850.4K783.5K4.08M8.47M1.04M618.8K771.3K2.89M917.5K
Short-term investments0
Receivables1.21M1.62M140.0K11.0K271.8K28.8K91.8K32.3K
Inventory-1.21M10-91.8K-32.3K
Current assets697.4K933.2K2.08M5.76M8.65M1.08M916.9K942.2K3.06M1.01M
Property, plant and equipment58.5K4791.02K3.89K4.82K02.64K
Total assets8.17M9.49M15.5M19.0M20.0M5.64M5.76M6.06M10.3M5.81M
Accounts payable1.16M542.8K720.9K399.8K221.3K448.9K105.7K308.1K567.8K117.4K
Current liabilities2.85M1.24M1.01M650.6K462.4K851.5K326.8K604.7K1.78M1.80M
Long-term debt0
Total debt1.55M20.3K3.74M
Total liabilities2.85M1.24M1.01M650.6K462.4K851.5K326.8K604.7K2.44M1.80M
Shareholders' equity5.32M8.25M14.4M18.4M19.6M4.79M5.43M5.46M7.91M4.01M
Shares outstanding90.0M72.0M64.2M64.2M61.2M5.53B5.50B5.50B38.1M15.9M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-2.37M-2.97M-2.40M-1.81M-1.11M418.0K-152.5K-2.11M707.1K-247.1K
Capital spending-4.11K0-900.0K-2.58M-7.25M-7.25M-75.8K-6.05K-6.05K-6.05K
Free cash flow-2.38M-2.97M-3.30M-4.39M-8.36M418.0K-152.5K-2.11M707.1K-247.1K
Cash from investing-68.8K0-900.0K-2.58M-7.25M-7.25M-7.25M-13.6K-13.6K53.9K
Cash from financing2.18M3.04M015.8M15.8M15.8M15.8M15.8M1.27M678.9K
Dividends paid-982.0K-663.5K
Share buybacks-36.1K-170.3K-842.0K-842.0K-842.0K-286.1K-15.4K
Change in cash-258.1K66.8K-3.30M-4.39M7.44M418.0K-152.5K-2.12M1.97M480.1K

Open Financials

Filings

FilingDateTypeFiled with
Invion Receives $0.5m R&D Tax Incentive RebateNov 18, 2026ResultsASX
Change of Director's Interest Notice - Thian ChewNov 17, 2026Ownership change noticeASX
Notification of cessation of securities - IVXNov 17, 2026FinancingASX
IVX Director Appointment/Resignation & New Company SecretaryNov 10, 2026Management or board changeASX
Appendix 4C and Quarterly Activities Report - September 2026Oct 28, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 23, 2026Meeting noticeASX
Proposed issue of securities - IVXOct 20, 2026FinancingASX
Funding Agreements Cover Up to 85% of Clinical Trials CostsOct 20, 2026FinancingASX
Funding Agreements Cover Up to 85% of Clinical Trials CostsOct 20, 2026FinancingASX
Photosoft & Novel Immunotherapy Collab PartnershipOct 19, 2026Other filingsASX
All 131 filings
FilingDateTypeFiled with
PER: Percheron and Invion Explore Cancer Combination TherapyOct 19, 2026Other filingsASX
Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2Oct 18, 2026Operations updateASX
Application for quotation of securities - IVXOct 15, 2026FinancingASX
Proposed issue of securities - IVXSep 29, 2026FinancingASX
Director LoansSep 29, 2026FinancingASX
Appendix 4G and Corporate Governance StatementAug 26, 2026Annual reportASX
Appendix 4E and Annual ReportAug 26, 2026Annual reportASX
Initial Director's Interest Notice - Paul FIeldAug 20, 2026Ownership change noticeASX
Final Director's Interest Notice - Alistair BennallackAug 20, 2026Ownership change noticeASX
IVX Credentialed International Biotech Leader Joins BoardAug 18, 2026Management or board changeASX
Appendix 4C and Quarterly Activities Report - June 2026Jul 30, 2026Quarterly reportASX
Photosoft Platform Expands to Eye Diseases Via PartnershipMay 18, 2026Operations updateASX
Appendix 4C and Quarterly Activities Report - March 2026Apr 30, 2026Quarterly reportASX
Skin Cancer Trial Moves to BCC With More Encouraging SignalsApr 21, 2026Operations updateASX
Appendix 4D and Half Year Financial ReportFeb 26, 2026Interim reportASX
Appendix 4C and Quarterly Activities Report - December 2025Jan 30, 2026Quarterly reportASX
Major Shareholders Lead Invion $1.3M Capital RaiseJan 30, 2026FinancingASX
Trading HaltJan 28, 2026Trading halt or suspensionASX
Pause in TradingJan 28, 2026Trading halt or suspensionASX
Hanlim & Korean Government Fund Pathway to Clinical TrialDec 22, 2025FinancingASX
Invion Secures Expanded Photosoft Global Exclusive LicenseDec 2, 2025Acquisition or disposalASX
Appendix 4C and Quarterly Activities Report - September 2025Oct 30, 2025Quarterly reportASX
Funded Collaboration Agreement with Protect Animal HealthOct 20, 2025Operations updateASX
Repayment of Lind Facility with Successful Capital RaiseOct 9, 2025FinancingASX
Response to ASX Aware LetterAug 27, 2025Explanation requestASX
Appendix 4E and Annual ReportAug 27, 2025Annual reportASX
Response to ASX Price QueryAug 20, 2025Explanation requestASX
Orphan Drug Designation Granted by U.S. FDA For Anal CancerAug 20, 2025Other filingsASX
Appendix 4C and Quarterly Activities Report - June 2025Jul 31, 2025Quarterly reportASX
Security Class Reinstatement to QuotationJul 17, 2025Trading halt or suspensionASX
Security Class Suspension from QuotationJul 10, 2025Trading halt or suspensionASX
Underwritten Loyalty Option Entitlement Offer ProspectusJun 23, 2025Offer documentASX
EQR Progresses Regional Tungsten Hub StrategyJun 13, 2025Other filingsASX
Loyalty Option Entitlement OfferJun 13, 2025FinancingASX
Encouraging SRC Findings on Ph I/II Skin Cancer TrialMay 28, 2025Operations updateASX
Dosing of 1st Six Patients in Phase I/II Skin Cancer TrialMay 1, 2025Operations updateASX
Appendix 4C and Quarterly Activities Report - March 2025Apr 30, 2025Quarterly reportASX
Share Purchase Agreement Termination and Tranche RepaymentMar 4, 2025Other filingsASX
Completion Of Placement to Accelerate Clinical ProgramsMar 4, 2025FinancingASX
Oesophageal Cancer Collaboration and Funding AgreementFeb 25, 2025Operations updateASX
Activities Report and Appendix 4CJan 30, 2025Quarterly reportASX
Invion Doses First Patient in Phase I/II Skin Cancer TrialDec 2, 2024Other filingsASX
Consolidation/Split - IVXOct 14, 2024Other filingsASX
Ph 2 Prostate Cancer Results Strong Safety and 40% ResponseSep 17, 2024Other filingsASX
Invion secures funding through an institutional placementJun 27, 2024FinancingASX
Agreement with Major South Korean Pharma Group HanlimMay 7, 2024Operations updateASX
INV043 With ICI Therapy Achieved 80% Tumour Control For ASCCMar 4, 2024Operations updateASX
Agreement with Dr.inB to develop Photosoft treatment for HPVFeb 22, 2024Operations updateASX
AGM PresentationNov 28, 2023Other filingsASX
Major Milestone towards Clinical TrialsNov 21, 2023Other filingsASX
Investor PresentationOct 23, 2023Other filingsASX
Photosoft Territory Expanded to South Korea for CancerSep 24, 2023Operations updateASX
Appendix 4E and Preliminary Financial ReportAug 30, 2023ResultsASX
Expansion of Territory Rights to USA, Canada and Hong KongFeb 7, 2023Other filingsASX
INV043 Effective Against Anal Cancer SCC In VitroSep 14, 2022Other filingsASX
Response to ASX Aware QuerySep 13, 2022Explanation requestASX
Photosoft Shows Activity Against Zika VirusSep 7, 2022Other filingsASX
INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPYMay 29, 2022Other filingsASX
Supplementary ProspectusNov 25, 2021Offer documentASX
ProspectusNov 22, 2021Offer documentASX
Share Purchase Plan Offer Booklet & Application FormNov 21, 2021FinancingASX
Capital Raising and expansion of Photosoft TerritoryNov 16, 2021FinancingASX
Further Information on Proof of Concept Pilot StudyOct 28, 2021Other filingsASX
Complete Regression of TNBC Tumours and Protective ImmunityOct 27, 2021Other filingsASX
Capital Raising & co-development for Photosoft TechnologyJun 2, 2021FinancingASX
Initial Proof-of-Concept results show INV043 to be effectiveMay 24, 2021Other filingsASX
App 4D and Financial Report for half year to 31 Dec 2020Feb 24, 2021Other filingsASX
Business Update and Change to Board and ManagementJul 28, 2020Operations updateASX
Activities Report and Appendix 4C June 2020 QuarterJul 28, 2020Quarterly reportASX
Invion subsidiary signs Supply Agreement with Pavay BiotechJun 30, 2020Other filingsASX
Appendix 4C - March 2020 quarterApr 20, 2020Quarterly reportASX
App 4D and Financial Report for half year to 31 Dec 2019Feb 24, 2020Other filingsASX
Invion signs R&D Services Agreement with Pavay BiotechFeb 2, 2020Other filingsASX
Appendix 4C - December 2019 quarterJan 29, 2020Quarterly reportASX
Additional Information to Prior AnnouncementNov 28, 2019Other filingsASX
Pre-clinical research agreement with Peter MacCallum CCOct 30, 2019Other filingsASX
Appendix 4C - September 2019 quarterOct 28, 2019Quarterly reportASX
Appendix 4E and Financial Report for year ended 30 June 2019Aug 28, 2019ResultsASX
COO Craig Newton to transition to Invion CEOJul 21, 2019Other filingsASX
Appendix 4C - June quarterJul 12, 2019Quarterly reportASX
Animal studies show IVX-P02 potential in metastatic cancersMay 27, 2019Other filingsASX
Quarterly UpdateApr 17, 2019Other filingsASX
Appendix 4D and Financial Report for Half Year to 31 Dec 18Feb 26, 2019Interim reportASX
Response to ASX Appendix 4C QueryFeb 20, 2019Explanation requestASX
Invion completes spin-out of respiratory assetsFeb 11, 2019Other filingsASX
General Meeting - Results of MeetingJan 30, 2019Meeting outcomeASX
Appendix 4C - December quarterJan 28, 2019Quarterly reportASX
Appendix 4C - September 2018 quarterOct 28, 2018Quarterly reportASX
New Photosoft formulation increased effect in ovarian cancerSep 24, 2018Other filingsASX
Spin out of respiratory assets for development in ChinaSep 4, 2018Other filingsASX
Appendix 4E Annual Report and Full Year Statutory AccountsAug 28, 2018Annual reportASX
Appendix 4C - June 2018 quarterJul 27, 2018Quarterly reportASX
Photosoft efficiently destroys ovarian cancer cells in vitroJul 4, 2018Other filingsASX
Appendix 4C - March 2018 quarterApr 25, 2018Quarterly reportASX
Invion alliance with Hudson Institute of Medical ResearchMar 19, 2018Other filingsASX
Completion iof Rights IssueMar 13, 2018FinancingASX
Appendix 4D and Financial Report for half year to 31 Dec 17Feb 27, 2018Interim reportASX
Rights Issue Information BookletFeb 11, 2018FinancingASX
Appendix 4C - December 2017 QuarterJan 28, 2018Quarterly reportASX
Appointment of Non Executive Director and ChairmanNov 30, 2017Management or board changeASX
AGM - Withdrawal of Resolution prior to MeetingNov 29, 2017Other filingsASX
AGM Notice of Meeting And Proxy FormOct 29, 2017Meeting noticeASX
Appendix 4C - cashflow statement for the September quarterOct 27, 2017Quarterly reportASX
Appendix 4G - Key to governance disclosuresOct 26, 2017Other filingsASX
Strategic Transaction UpdateSep 5, 2017Other filingsASX
Appendix 4E and Full Year Statutory AccountsAug 31, 2017Annual reportASX
Appendix 4C - quarterlyJul 30, 2017Quarterly reportASX
Invion announces strategic allianceApr 18, 2017Other filingsASX
Appendix 4D and Financial Report for half year to 31 Dec 16Feb 27, 2017Interim reportASX
Appendix 4C December quarterJan 30, 2017Quarterly reportASX
Appendix 4C for the September quarterOct 30, 2016Quarterly reportASX
Receipt of R&T tax rebateSep 12, 2016Other filingsASX
App 4E, Annual and Financial Report FY2016Aug 30, 2016Other filingsASX
Response to ASX Appendix 4C queryAug 8, 2016Explanation requestASX
Phase 2 data presented to American Thoracic SocietyMay 20, 2016Other filingsASX
End of Phase 2 Meeting for INV102 (nadolol)Apr 3, 2016Other filingsASX
Invion announces no secondary capital raiseMar 30, 2016Other filingsASX
Smoking cessation patent allowance and Operational updateMar 10, 2016Other filingsASX
Appendix 4D and Half Year AccountsFeb 26, 2016Interim reportASX
Invion completes SPP and PlacementFeb 11, 2016FinancingASX
Smoking cessation trial results of ongoing data analysisFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Invion Ltd.’s releases · as of Sep 29, 2026

Common shares
110,553,134
Fully diluted
110,553,134

Fully diluted

LineShares
Common shares110,553,134

Share count over time

CountShares
Nov 22, 2026110,553,134

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alan YamashitaNon-Executive Director · Since at least Nov 12, 2026
Louise WhiteExecutive Manager · Since at least Nov 11, 2026
Melanie LeydinNon-Executive Director, Company Secretary & CFO · Since at least Nov 12, 2026
Paul FieldNon-Executive Director · Since at least Nov 12, 2026
Robert RamsayChair of the Board · Since at least Nov 11, 2026
Sebastian MarcuccioFounder and Director at Advanced Molecular Technologies Pty Ltd (AMT) · Nov 4, 2026 – Nov 12, 2026 · Past
Thian ChewExecutive Chair and CEO · Since at least Nov 12, 2026

Open People

Log in to ask 6ix AI your own questions about Invion Ltd.